ArticleBMC ophthalmology2026
Achieving low intraocular pressure in normal-tension glaucoma with the Preserflo MicroShunt: comparison with primary open-angle glaucoma and the XEN-45 Gel Stent.
Article in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAchieving low intraocular pressure (IOP) while minimizing surgical risk remains a central challenge in the management of normal-tension glaucoma (NTG). This study aimed to evaluate the efficacy and safety of the Preserflo MicroShunt (PMS) in NTG compared with primary open-angle glaucoma (POAG) and the XEN-45 Gel Stent.
methodsIn this retrospective dual-comparison study, the primary outcomes were 2-year complete success (≥ 30% reduction in IOP from baseline and ≤ 12 mmHg without medication) and hazard ratios (HRs) for surgical failure. Kaplan-Meier analyses and univariate Cox models were used to compare NTG PMS and POAG PMS patients (1:1 matched cohort; PMS analysis) and exploratory multivariable models for consecutive NTG PMS and NTG XEN-45 patients (NTG analysis). Secondary outcomes included bleb revision and complication rates.
resultsIn the PMS analysis, 50 NTG patients were matched to 50 POAG patients. Two-year success rates were 69% and 45%, respectively (p = 0.0277). NTG diagnosis was associated with a lower risk of failure (HR 0.48, 95% CI 0.24-0.96) and fewer bleb revisions. In the NTG analysis, 45 PMS patients were compared with 23 XEN-45 patients. Two-year success rates were 71% and 17%, respectively (p < 0.0001). PMS implantation was associated with a lower risk of failure (HR 0.25, 95% CI 0.12-0.53) and fewer needling procedures. No sight-threatening complications occurred in any group.
conclusionsPMS implantation enabled a high rate of sustained low IOP control, with significantly higher success rates than in matched POAG patients and NTG XEN-45 patients, while requiring fewer postoperative interventions. These findings indicate that the PMS might achieve lower IOP thresholds in NTG than previously expected requiring evaluation in larger prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.